Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Xtandi	Capsule	40 mg	Oral	Astellas Pharma Inc	2013-06-07	Not applicable
Xtandi	Capsule	40 mg/1	Oral	Astellas Pharma Inc	2012-08-31	Not applicable
Xtandi	Capsule	40 mg	Oral	Astellas Pharma Europe Bv	2013-06-21	Not applicable

Categories

UNII

93T0T9GKNU

CAS number

915087-33-1

Weight

Average: 464.436
Monoisotopic: 464.093009286

Chemical Formula

C₂₁H₁₆F₄N₄O₂S

InChI Key

WXCXUHSOUPDCQV-UHFFFAOYSA-N

InChI

InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)

IUPAC Name

4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide

SMILES

CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F

Pharmacology

Indication

Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Structured Indications

Metastatic Castration Resistant Prostate Cancer

Pharmacodynamics

Resitance to enzalutamide therapy has been observed. This may occurred due to an upregulation of NF-κB2/p52.

Mechanism of action

Enzalutamide is a competitive androgen receptor inhibitor that effects multiple stages of the signalling pathway. It is able to inhibit androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with DNA. As a result, proliferation of prostate cancer cells decreases which ultimately leads to apoptosis and decreased tumour volume.

Target	Actions	Organism
AAndrogen receptor	inhibitor	Human

Absorption

The pharmacokinetic profile of enzalutamide and N-desmethyl enzalutamide (its major active metabolite) is described by a linear two-compartment model with first-order absorption. Enzalutamide also accumulates. Food does not affect its absorption. Tmax, prostate cancer patients = 1 hour (range of 0.5-3 hours); Cmax, steady state, enzalutamide = 16.6 μg/mL; Cmax, steady state, N-desmethyl enzalutamide = 12.7 μg/mL; Time to steady state, daily dosing = 28 days;

Volume of distribution

Apparent volume of distribution (Vd/F), single oral dose = 110 L

Protein binding

Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins.

Metabolism

Enzalutamide is hepatically metabolized, primarily by CYP2C8 and CYP3A4. The enzyme that converts enzalutamide to its active metabolite, N-desmethyl enzalutamide, is CYP2C8. The activity of N-desmethyl-enzalutamide is similar to that of the parent compound.

Route of elimination

Enzalutamide is primarily eliminated by hepatic metabolism. 71% of the dose is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).

Half life

The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.

Clearance

Apparent clearance (CL/F), single oral dose = 0.56 L/h (range of 0.33 - 1.02 L/h)

Toxicity

The most common adverse reactions (≥ 5%) are asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskeletal pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower respiratory infection, spinal cord compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and hypertension.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be decreased when it is combined with Enzalutamide.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
5-androstenedione	The serum concentration of 5-androstenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
Abemaciclib	The serum concentration of Abemaciclib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Abiraterone	The serum concentration of Abiraterone can be decreased when it is combined with Enzalutamide.	Approved
Acenocoumarol	The serum concentration of Acenocoumarol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Enzalutamide.	Approved
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Enzalutamide.	Approved
Acetyldigoxin	Acetyldigoxin may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Adinazolam	The serum concentration of Adinazolam can be decreased when it is combined with Enzalutamide.	Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Enzalutamide.	Approved
Albendazole	The serum concentration of Albendazole can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Alclometasone	The serum concentration of Alclometasone can be decreased when it is combined with Enzalutamide.	Approved
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Enzalutamide.	Experimental, Investigational
Alfentanil	The serum concentration of Alfentanil can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aliskiren	The serum concentration of Aliskiren can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Allylestrenol	The serum concentration of Allylestrenol can be decreased when it is combined with Enzalutamide.	Approved
Almotriptan	The serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Alogliptin	The serum concentration of Alogliptin can be decreased when it is combined with Enzalutamide.	Approved
Alosetron	The serum concentration of Alosetron can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
alpha-Tocopherol acetate	The serum concentration of alpha-Tocopherol acetate can be decreased when it is combined with Enzalutamide.	Approved
Alprazolam	The serum concentration of Alprazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ambroxol	The serum concentration of Ambroxol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Amcinonide	The serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide.	Approved
Aminophenazone	The serum concentration of Aminophenazone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Aminophylline	The serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide.	Approved
Amiodarone	The serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be decreased when it is combined with Enzalutamide.	Approved
Amlodipine	The serum concentration of Amlodipine can be decreased when it is combined with Enzalutamide.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Enzalutamide.	Approved, Investigational
Amprenavir	The serum concentration of Amprenavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ancestim	The risk or severity of cytotoxicity can be increased when Ancestim is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Androstenedione	The serum concentration of Androstenedione can be decreased when it is combined with Enzalutamide.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be decreased when it is combined with Enzalutamide.	Investigational
anecortave acetate	The serum concentration of anecortave acetate can be decreased when it is combined with Enzalutamide.	Investigational
Antipyrine	The serum concentration of Antipyrine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Apalutamide	The serum concentration of Enzalutamide can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Enzalutamide.	Approved
Apremilast	The serum concentration of Apremilast can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aprepitant	The serum concentration of Aprepitant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Argatroban	The serum concentration of Argatroban can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Artemether	The serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved
Artemether	The serum concentration of Artemether can be decreased when it is combined with Enzalutamide.	Approved
Asenapine	The serum concentration of Asenapine can be decreased when it is combined with Enzalutamide.	Approved
Astemizole	The serum concentration of Astemizole can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Atamestane	The serum concentration of Atamestane can be decreased when it is combined with Enzalutamide.	Investigational
Atazanavir	The serum concentration of Atazanavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Atomoxetine	The metabolism of Enzalutamide can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Enzalutamide.	Approved
Avanafil	The serum concentration of Avanafil can be decreased when it is combined with Enzalutamide.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Azelastine	The serum concentration of Azelastine can be decreased when it is combined with Enzalutamide.	Approved
Azithromycin	The serum concentration of Azithromycin can be decreased when it is combined with Enzalutamide.	Approved
Banoxantrone	The serum concentration of Banoxantrone can be decreased when it is combined with Enzalutamide.	Investigational
Baricitinib	The serum concentration of Baricitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Beclomethasone dipropionate	The serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be decreased when it is combined with Enzalutamide.	Approved
Benidipine	The serum concentration of Benidipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Benzphetamine	The serum concentration of Benzphetamine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Benzyl alcohol	The serum concentration of Benzyl alcohol can be decreased when it is combined with Enzalutamide.	Approved
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Bevacizumab	Bevacizumab may increase the cardiotoxic activities of Enzalutamide.	Approved, Investigational
Bexarotene	The serum concentration of Bexarotene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bezafibrate	The serum concentration of Bezafibrate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bicalutamide	The serum concentration of Bicalutamide can be decreased when it is combined with Enzalutamide.	Approved
Bictegravir	The serum concentration of Bictegravir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bisoprolol	The serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.	Approved
Blonanserin	The serum concentration of Blonanserin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Boceprevir	The serum concentration of Boceprevir can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Bortezomib	The serum concentration of Bortezomib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Enzalutamide.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Brigatinib	The serum concentration of Brigatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Brinzolamide	The serum concentration of Brinzolamide can be decreased when it is combined with Enzalutamide.	Approved
Brivaracetam	The serum concentration of Brivaracetam can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Bromazepam	The serum concentration of Bromazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Bromocriptine	The serum concentration of Bromocriptine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Brompheniramine	The serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide.	Approved
Budesonide	The serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.	Approved
Bupivacaine	The serum concentration of Bupivacaine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Buprenorphine	The serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The serum concentration of Bupropion can be decreased when it is combined with Enzalutamide.	Approved
Buspirone	The serum concentration of Buspirone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Busulfan	The serum concentration of Busulfan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide.	Approved
Cabergoline	The serum concentration of Cabergoline can be decreased when it is combined with Enzalutamide.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Enzalutamide.	Approved
Calcitriol	The serum concentration of Calcitriol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Enzalutamide.	Approved
Cannabidiol	The serum concentration of Cannabidiol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Carbamazepine	The serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The serum concentration of Carbinoxamine can be decreased when it is combined with Enzalutamide.	Approved
Cariprazine	The serum concentration of Cariprazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Carvedilol	The serum concentration of Carvedilol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Celecoxib	The serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Celiprolol	The serum concentration of Celiprolol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cephalexin	The serum concentration of Cephalexin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be decreased when it is combined with Enzalutamide.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Cevimeline	The serum concentration of Cevimeline can be decreased when it is combined with Enzalutamide.	Approved
Chenodeoxycholic acid	The serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Enzalutamide.	Approved
Chlordiazepoxide	The serum concentration of Chlordiazepoxide can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Chlorphenamine	The serum concentration of Chlorphenamine can be decreased when it is combined with Enzalutamide.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Chlorzoxazone	The serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide.	Approved
Cholecalciferol	The serum concentration of Cholecalciferol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Ciclesonide	The serum concentration of Ciclesonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cinacalcet	The serum concentration of Cinacalcet can be decreased when it is combined with Enzalutamide.	Approved
Cisapride	The serum concentration of Cisapride can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Citalopram can be decreased when it is combined with Enzalutamide.	Approved
Clarithromycin	The serum concentration of Clarithromycin can be decreased when it is combined with Enzalutamide.	Approved
Clemastine	The metabolism of Enzalutamide can be decreased when combined with Clemastine.	Approved, Investigational
Clindamycin	The serum concentration of Clindamycin can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide.	Approved
Clobetasone	The serum concentration of Clobetasone can be decreased when it is combined with Enzalutamide.	Approved
Clocortolone	The serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.	Approved
Clofazimine	The serum concentration of Clofazimine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Clofibrate	The serum concentration of Clofibrate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
clomethiazole	The serum concentration of clomethiazole can be decreased when it is combined with Enzalutamide.	Investigational
Clomipramine	The serum concentration of Clomipramine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Clonazepam	The serum concentration of Clonazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Enzalutamide.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Enzalutamide.	Approved
Clorazepate	The serum concentration of Clorazepate can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clotiazepam	The serum concentration of Clotiazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Clotrimazole	The metabolism of Enzalutamide can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be decreased when it is combined with Enzalutamide.	Approved
Cobicistat	The serum concentration of Enzalutamide can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cocaine	The serum concentration of Cocaine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Codeine	The serum concentration of Codeine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be decreased when it is combined with Enzalutamide.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Enzalutamide.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated estrogens can be decreased when it is combined with Enzalutamide.	Approved
Copanlisib	The serum concentration of Copanlisib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cortexolone 17α-propionate	The serum concentration of Cortexolone 17α-propionate can be decreased when it is combined with Enzalutamide.	Investigational
Corticosterone	The serum concentration of Corticosterone can be decreased when it is combined with Enzalutamide.	Experimental
Cortisone acetate	The serum concentration of Cortisone acetate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Crisaborole	The metabolism of Enzalutamide can be decreased when combined with Crisaborole.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be decreased when it is combined with Enzalutamide.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.	Approved
Cyclophosphamide	The serum concentration of Cyclophosphamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Cymarin	Cymarin may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Cytarabine	The serum concentration of Cytarabine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.	Approved
Dabrafenib	The serum concentration of Enzalutamide can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Daclatasvir	The serum concentration of Daclatasvir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dantrolene	The serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.	Approved
Dapsone	The serum concentration of Dapsone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Darifenacin	The serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Darunavir	The serum concentration of Darunavir can be decreased when it is combined with Enzalutamide.	Approved
Dasabuvir	The serum concentration of Dasabuvir can be decreased when it is combined with Enzalutamide.	Approved
Dasatinib	The serum concentration of Dasatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Enzalutamide.	Approved
Deferasirox	The serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The serum concentration of Deflazacort can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Enzalutamide.	Approved
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Enzalutamide.	Approved
Desonide	The serum concentration of Desonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Desoximetasone	The serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Enzalutamide.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Enzalutamide.	Experimental, Vet Approved
Desvenlafaxine	The serum concentration of Desvenlafaxine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Deutetrabenazine	The serum concentration of Deutetrabenazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dexamethasone	The serum concentration of Dexamethasone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Enzalutamide.	Vet Approved
Dexchlorpheniramine maleate	The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Enzalutamide.	Approved
Dexlansoprazole	The serum concentration of Dexlansoprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dextromethorphan	The serum concentration of Dextromethorphan can be decreased when it is combined with Enzalutamide.	Approved
Dextropropoxyphene	The serum concentration of Dextropropoxyphene can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Withdrawn
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Vet Approved
Diclofenac	The serum concentration of Diclofenac can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Enzalutamide.	Approved
Diflorasone	The serum concentration of Diflorasone can be decreased when it is combined with Enzalutamide.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Difluprednate	The serum concentration of Difluprednate can be decreased when it is combined with Enzalutamide.	Approved
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be decreased when it is combined with Enzalutamide.	Approved
Digoxin Immune Fab (Ovine)	Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enzalutamide.	Approved
Dihydrocodeine	The serum concentration of Dihydrocodeine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Dihydroergotamine	The serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Diltiazem	The serum concentration of Diltiazem can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Disopyramide	The serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.	Approved
Disulfiram	The serum concentration of Disulfiram can be decreased when it is combined with Enzalutamide.	Approved
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Dolasetron	The serum concentration of Dolasetron can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Donepezil	The serum concentration of Donepezil can be decreased when it is combined with Enzalutamide.	Approved
Dorzolamide	The serum concentration of Dorzolamide can be decreased when it is combined with Enzalutamide.	Approved
Doxepin	The serum concentration of Doxepin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Doxycycline	The metabolism of Enzalutamide can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be decreased when it is combined with Enzalutamide.	Approved
Dutasteride	The serum concentration of Dutasteride can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Enzalutamide.	Approved
Efavirenz	The serum concentration of Efavirenz can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Elbasvir	The serum concentration of Elbasvir can be decreased when it is combined with Enzalutamide.	Approved
Eletriptan	The serum concentration of Eletriptan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be decreased when it is combined with Enzalutamide.	Approved
Elvitegravir	The serum concentration of Elvitegravir can be decreased when it is combined with Enzalutamide.	Approved
Enalapril	The serum concentration of Enalapril can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Enasidenib	The serum concentration of Enasidenib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be decreased when it is combined with Enzalutamide.	Approved
Equilenin	The serum concentration of Equilenin can be decreased when it is combined with Enzalutamide.	Experimental
Equilin	The serum concentration of Equilin can be decreased when it is combined with Enzalutamide.	Approved
Ergocalciferol	The serum concentration of Ergocalciferol can be decreased when it is combined with Enzalutamide.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.	Approved
Ergonovine	The serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.	Approved
Ergotamine	The serum concentration of Ergotamine can be decreased when it is combined with Enzalutamide.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Erythromycin	The serum concentration of Erythromycin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Escitalopram	The serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Esomeprazole	The serum concentration of Esomeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol acetate	The serum concentration of Estradiol acetate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol benzoate	The serum concentration of Estradiol benzoate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol cypionate	The serum concentration of Estradiol cypionate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The serum concentration of Estradiol dienanthate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estradiol valerate	The serum concentration of Estradiol valerate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Estramustine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Enzalutamide.	Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Enzalutamide.	Approved
Estrone sulfate	The serum concentration of Estrone sulfate can be decreased when it is combined with Enzalutamide.	Approved
Eszopiclone	The serum concentration of Eszopiclone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ethanol	The serum concentration of Ethanol can be decreased when it is combined with Enzalutamide.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enzalutamide.	Approved
Ethosuximide	The serum concentration of Ethosuximide can be decreased when it is combined with Enzalutamide.	Approved
Ethylmorphine	The serum concentration of Ethylmorphine can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Etizolam	The serum concentration of Etizolam can be decreased when it is combined with Enzalutamide.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Enzalutamide.	Approved
Etoricoxib	The serum concentration of Etoricoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Enzalutamide.	Approved
Everolimus	The serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.	Approved
Exemestane	The serum concentration of Exemestane can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Famciclovir	The serum concentration of Famciclovir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Felbamate	The serum concentration of Felbamate can be decreased when it is combined with Enzalutamide.	Approved
Felodipine	The serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fenofibrate	The serum concentration of Fenofibrate can be decreased when it is combined with Enzalutamide.	Approved
Fentanyl	The serum concentration of Fentanyl can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Enzalutamide.	Approved
Finasteride	The serum concentration of Finasteride can be decreased when it is combined with Enzalutamide.	Approved
Fingolimod	The serum concentration of Fingolimod can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Flibanserin	The serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fluasterone	The serum concentration of Fluasterone can be decreased when it is combined with Enzalutamide.	Investigational
Fluconazole	The metabolism of Enzalutamide can be decreased when combined with Fluconazole.	Approved, Investigational
Fludrocortisone	The serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Flumethasone	The serum concentration of Flumethasone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Flunisolide	The serum concentration of Flunisolide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Flunitrazepam	The serum concentration of Flunitrazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Fluorometholone	The serum concentration of Fluorometholone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fluoxetine	The serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Fluprednidene	The serum concentration of Fluprednidene can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be decreased when it is combined with Enzalutamide.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be decreased when it is combined with Enzalutamide.	Approved
Flurazepam	The serum concentration of Flurazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Flutamide	The serum concentration of Flutamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Enzalutamide.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be decreased when it is combined with Enzalutamide.	Approved
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Enzalutamide.	Approved
Fluvoxamine	The metabolism of Enzalutamide can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Fosamprenavir	The serum concentration of Fosamprenavir can be decreased when it is combined with Enzalutamide.	Approved
Fosaprepitant	The serum concentration of Enzalutamide can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Enzalutamide can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Fulvestrant	The serum concentration of Fulvestrant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Fusidic Acid	The serum concentration of Enzalutamide can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Galantamine	The serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.	Approved
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Gemfibrozil	The serum concentration of Gemfibrozil can be decreased when it is combined with Enzalutamide.	Approved
Gitoformate	Gitoformate may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Glipizide	The serum concentration of Glipizide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Glyburide	The serum concentration of Glyburide can be decreased when it is combined with Enzalutamide.	Approved
Granisetron	The serum concentration of Granisetron can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Enzalutamide.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Guanfacine	The serum concentration of Guanfacine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Halcinonide	The serum concentration of Halcinonide can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be decreased when it is combined with Enzalutamide.	Approved
Haloperidol	The serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.	Approved
Halothane	The serum concentration of Halothane can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be decreased when it is combined with Enzalutamide.	Investigational
Hexobarbital	The serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide.	Approved
Histamine	The serum concentration of Histamine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Hydrocodone	The serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Hydromorphone	The serum concentration of Hydromorphone can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Enzalutamide.	Approved
Icotinib	The serum concentration of Icotinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Idelalisib	The serum concentration of Idelalisib can be decreased when it is combined with Enzalutamide.	Approved
Ifosfamide	The serum concentration of Ifosfamide can be decreased when it is combined with Enzalutamide.	Approved
Iloperidone	The serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.	Approved
Imatinib	The serum concentration of Imatinib can be decreased when it is combined with Enzalutamide.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Imipramine	The serum concentration of Imipramine can be decreased when it is combined with Enzalutamide.	Approved
Imiquimod	The serum concentration of Imiquimod can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.	Approved
Indapamide	The serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.	Approved
Indinavir	The serum concentration of Indinavir can be decreased when it is combined with Enzalutamide.	Approved
Ipratropium bromide	The serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.	Approved
Irbesartan	The metabolism of Enzalutamide can be decreased when combined with Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Isavuconazole	The serum concentration of Isavuconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Enzalutamide resulting in a loss in efficacy.	Approved, Investigational
Isosorbide Dinitrate	The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Isosorbide Mononitrate	The serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide.	Approved
Isradipine	The serum concentration of Isradipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Istaroxime	The serum concentration of Istaroxime can be decreased when it is combined with Enzalutamide.	Investigational
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be decreased when it is combined with Enzalutamide.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be decreased when it is combined with Enzalutamide.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ixazomib	The serum concentration of Ixazomib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ketamine	The serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Enzalutamide.	Approved
Ketobemidone	The serum concentration of Ketobemidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lacidipine	The serum concentration of Lacidipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lanatoside C	Lanatoside C may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Laquinimod	The serum concentration of Laquinimod can be decreased when it is combined with Enzalutamide.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Enzalutamide.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lercanidipine	The serum concentration of Lercanidipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Letermovir	The serum concentration of Enzalutamide can be increased when it is combined with Letermovir.	Approved, Investigational
Letrozole	The serum concentration of Letrozole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levocetirizine	The serum concentration of Levocetirizine can be decreased when it is combined with Enzalutamide.	Approved
Levomethadyl Acetate	The serum concentration of Levomethadyl Acetate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Levothyroxine	The serum concentration of Levothyroxine can be decreased when it is combined with Enzalutamide.	Approved
Lidocaine	The serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.	Approved
Lisuride	The serum concentration of Lisuride can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lomitapide	The serum concentration of Lomitapide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Enzalutamide.	Approved
Lopinavir	The serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.	Approved
Loratadine	The serum concentration of Loratadine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Lorcaserin	The serum concentration of Lorcaserin can be decreased when it is combined with Enzalutamide.	Approved
Lorpiprazole	The serum concentration of Enzalutamide can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Enzalutamide.	Approved
Loteprednol	The serum concentration of Loteprednol can be decreased when it is combined with Enzalutamide.	Approved
Lovastatin	The serum concentration of Lovastatin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Luliconazole	The serum concentration of Enzalutamide can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Enzalutamide can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be decreased when it is combined with Enzalutamide.	Approved
Lurasidone	The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Macimorelin	The serum concentration of Macimorelin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Macitentan	The serum concentration of Macitentan can be decreased when it is combined with Enzalutamide.	Approved
Maraviroc	The serum concentration of Maraviroc can be decreased when it is combined with Enzalutamide.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be decreased when it is combined with Enzalutamide.	Investigational
Mebendazole	The serum concentration of Mebendazole can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Medical Cannabis	The serum concentration of Medical Cannabis can be decreased when it is combined with Enzalutamide.	Experimental
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be decreased when it is combined with Enzalutamide.	Approved
Mefloquine	The serum concentration of Mefloquine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Melengestrol	The serum concentration of Melengestrol can be decreased when it is combined with Enzalutamide.	Vet Approved
Meloxicam	The serum concentration of Meloxicam can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Methadone	The serum concentration of Methadone can be decreased when it is combined with Enzalutamide.	Approved
Methaqualone	The serum concentration of Methaqualone can be decreased when it is combined with Enzalutamide.	Illicit, Withdrawn
Methoxsalen	The serum concentration of Methoxsalen can be decreased when it is combined with Enzalutamide.	Approved
Methoxyflurane	The serum concentration of Methoxyflurane can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Methyltestosterone	The serum concentration of Methyltestosterone can be decreased when it is combined with Enzalutamide.	Approved
Metildigoxin	Metildigoxin may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Enzalutamide.	Approved, Investigational
Metronidazole	The serum concentration of Metronidazole can be decreased when it is combined with Enzalutamide.	Approved
Mexiletine	The serum concentration of Mexiletine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mianserin	The serum concentration of Mianserin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mibefradil	The serum concentration of Mibefradil can be decreased when it is combined with Enzalutamide.	Investigational, Withdrawn
Miconazole	The serum concentration of Miconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Midostaurin	The serum concentration of Midostaurin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mifepristone	The serum concentration of Mifepristone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide.	Approved
Mirtazapine	The serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide.	Approved
Mitotane	The serum concentration of Enzalutamide can be decreased when it is combined with Mitotane.	Approved
Modafinil	The serum concentration of Modafinil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mometasone	The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Montelukast	The serum concentration of Montelukast can be decreased when it is combined with Enzalutamide.	Approved
Morphine	The serum concentration of Morphine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nabiximols	The serum concentration of Nabiximols can be decreased when it is combined with Enzalutamide.	Approved
Naloxegol	The serum concentration of Naloxegol can be decreased when it is combined with Enzalutamide.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Nateglinide	The serum concentration of Nateglinide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be decreased when it is combined with Enzalutamide.	Investigational
Nefazodone	The serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Nelfinavir	The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide.	Approved
Neratinib	The serum concentration of Neratinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Netupitant	The serum concentration of Netupitant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nevirapine	The serum concentration of Enzalutamide can be decreased when it is combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nicotine	The serum concentration of Nicotine can be decreased when it is combined with Enzalutamide.	Approved
Nifedipine	The serum concentration of Nifedipine can be decreased when it is combined with Enzalutamide.	Approved
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nilvadipine	The serum concentration of Nilvadipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nimodipine	The serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Nisoldipine	The serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.	Approved
Nitrazepam	The serum concentration of Nitrazepam can be decreased when it is combined with Enzalutamide.	Approved
Nitrendipine	The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Enzalutamide.	Approved
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Enzalutamide.	Approved
Nortriptyline	The serum concentration of Nortriptyline can be decreased when it is combined with Enzalutamide.	Approved
Odanacatib	The serum concentration of Odanacatib can be decreased when it is combined with Enzalutamide.	Investigational
Olaparib	The serum concentration of Olaparib can be decreased when it is combined with Enzalutamide.	Approved
Oleandrin	Oleandrin may decrease the cardiotoxic activities of Enzalutamide.	Experimental, Investigational
Oleoyl-estrone	The serum concentration of Oleoyl-estrone can be decreased when it is combined with Enzalutamide.	Investigational
Olopatadine	The serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.	Approved
Omeprazole	The serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Ondansetron	The serum concentration of Ondansetron can be decreased when it is combined with Enzalutamide.	Approved
Opium	The serum concentration of Opium can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Orphenadrine	The serum concentration of Orphenadrine can be decreased when it is combined with Enzalutamide.	Approved
Osimertinib	The serum concentration of Osimertinib can be decreased when it is combined with Enzalutamide.	Approved
Ospemifene	The serum concentration of Ospemifene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ouabain	Ouabain may decrease the cardiotoxic activities of Enzalutamide.	Approved
Oxazepam	The serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Oxycodone	The serum concentration of Oxycodone can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Oxymorphone	The serum concentration of Oxymorphone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Palonosetron	The serum concentration of Palonosetron can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pantoprazole	The serum concentration of Pantoprazole can be decreased when it is combined with Enzalutamide.	Approved
Paramethadione	The serum concentration of Paramethadione can be decreased when it is combined with Enzalutamide.	Approved
Paramethasone	The serum concentration of Paramethasone can be decreased when it is combined with Enzalutamide.	Approved
Parecoxib	The serum concentration of Parecoxib can be decreased when it is combined with Enzalutamide.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Paritaprevir	The serum concentration of Paritaprevir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.	Approved
Pentamidine	The serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pentobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Perampanel	The serum concentration of Perampanel can be decreased when it is combined with Enzalutamide.	Approved
Pergolide	The serum concentration of Pergolide can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved, Withdrawn
Perhexiline	The serum concentration of Perhexiline can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Permethrin	The serum concentration of Permethrin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Perospirone	The serum concentration of Perospirone can be decreased when it is combined with Enzalutamide.	Approved
Perphenazine	The serum concentration of Perphenazine can be decreased when it is combined with Enzalutamide.	Approved
Peruvoside	Peruvoside may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Pethidine	The serum concentration of Pethidine can be decreased when it is combined with Enzalutamide.	Approved
Phenacetin	The serum concentration of Phenacetin can be decreased when it is combined with Enzalutamide.	Withdrawn
Phenobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenoxybenzamine	The serum concentration of Phenoxybenzamine can be decreased when it is combined with Enzalutamide.	Approved
Phenprocoumon	The serum concentration of Phenprocoumon can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Phenytoin	The serum concentration of Enzalutamide can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pilocarpine	The serum concentration of Pilocarpine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pimecrolimus	The serum concentration of Pimecrolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be decreased when it is combined with Enzalutamide.	Approved
Pinacidil	The serum concentration of Pinacidil can be decreased when it is combined with Enzalutamide.	Approved
Pioglitazone	The serum concentration of Pioglitazone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Piperaquine	The serum concentration of Piperaquine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pipotiazine	The serum concentration of Pipotiazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Pitolisant	The serum concentration of Pitolisant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Podofilox	The serum concentration of Podofilox can be decreased when it is combined with Enzalutamide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Posaconazole	The serum concentration of Posaconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Prasterone	The serum concentration of Prasterone can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The serum concentration of Prasterone sulfate can be decreased when it is combined with Enzalutamide.	Investigational
Prasugrel	The serum concentration of Prasugrel can be decreased when it is combined with Enzalutamide.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide.	Approved
Prazepam	The serum concentration of Prazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Praziquantel	The serum concentration of Praziquantel can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Prednicarbate	The serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Pregnenolone	The serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide.	Approved, Experimental, Investigational
Primaquine	The serum concentration of Primaquine can be decreased when it is combined with Enzalutamide.	Approved
Primidone	The serum concentration of Enzalutamide can be decreased when it is combined with Primidone.	Approved, Vet Approved
Prochlorperazine	The serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Proguanil	The serum concentration of Proguanil can be decreased when it is combined with Enzalutamide.	Approved
Promazine	The serum concentration of Promazine can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Propafenone	The serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.	Approved
Propiverine	The serum concentration of Propiverine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Propofol	The serum concentration of Propofol can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Propoxyphene napsylate	The serum concentration of Propoxyphene napsylate can be decreased when it is combined with Enzalutamide.	Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Proscillaridin	Proscillaridin may decrease the cardiotoxic activities of Enzalutamide.	Experimental
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Enzalutamide.	Approved
Pyrazinamide	The serum concentration of Pyrazinamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Quazepam	The serum concentration of Quazepam can be decreased when it is combined with Enzalutamide.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.	Approved
Quinacrine	The serum concentration of Quinacrine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Quinine	The serum concentration of Quinine can be decreased when it is combined with Enzalutamide.	Approved
Rabeprazole	The serum concentration of Rabeprazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Raloxifene	The serum concentration of Raloxifene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ranolazine	The serum concentration of Ranolazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Reboxetine	The serum concentration of Reboxetine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Regorafenib	The serum concentration of Regorafenib can be decreased when it is combined with Enzalutamide.	Approved
Repaglinide	The serum concentration of Repaglinide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Retapamulin	The serum concentration of Retapamulin can be decreased when it is combined with Enzalutamide.	Approved
Ribociclib	The serum concentration of Ribociclib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Rifabutin	The serum concentration of Enzalutamide can be decreased when it is combined with Rifabutin.	Approved, Investigational
Rifampicin	The serum concentration of Enzalutamide can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Enzalutamide can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Enzalutamide.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Enzalutamide.	Approved
Rimexolone	The serum concentration of Rimexolone can be decreased when it is combined with Enzalutamide.	Approved
Rimonabant	The serum concentration of Rimonabant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Enzalutamide.	Approved
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ritonavir	The serum concentration of Ritonavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Enzalutamide.	Approved
Rofecoxib	The serum concentration of Rofecoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Roflumilast	The serum concentration of Roflumilast can be decreased when it is combined with Enzalutamide.	Approved
Rolapitant	The serum concentration of Rolapitant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ropinirole	The serum concentration of Ropinirole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ropivacaine	The serum concentration of Ropivacaine can be decreased when it is combined with Enzalutamide.	Approved
Rosiglitazone	The metabolism of Enzalutamide can be decreased when combined with Rosiglitazone.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Enzalutamide.	Approved
Rotigotine	The serum concentration of Rotigotine can be decreased when it is combined with Enzalutamide.	Approved
Roxithromycin	The serum concentration of Roxithromycin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Rucaparib	The serum concentration of Rucaparib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Rupatadine	The serum concentration of Rupatadine can be decreased when it is combined with Enzalutamide.	Approved
Ruxolitinib	The serum concentration of Ruxolitinib can be decreased when it is combined with Enzalutamide.	Approved
Safinamide	The serum concentration of Safinamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Salmeterol	The serum concentration of Salmeterol can be decreased when it is combined with Enzalutamide.	Approved
Saquinavir	The serum concentration of Saquinavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Enzalutamide can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be decreased when it is combined with Enzalutamide.	Approved
Secobarbital	The serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.	Approved, Vet Approved
Selegiline	The serum concentration of Selegiline can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Enzalutamide.	Approved
Seratrodast	The serum concentration of Seratrodast can be decreased when it is combined with Enzalutamide.	Approved
Sertindole	The serum concentration of Sertindole can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Sertraline	The serum concentration of Sertraline can be decreased when it is combined with Enzalutamide.	Approved
Sevoflurane	The serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Sibutramine	The serum concentration of Sibutramine can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Enzalutamide.	Approved
Siltuximab	The serum concentration of Enzalutamide can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Simeprevir can be decreased when it is combined with Enzalutamide.	Approved
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Enzalutamide.	Approved
Sirolimus	The serum concentration of Sirolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Solifenacin	The serum concentration of Solifenacin can be decreased when it is combined with Enzalutamide.	Approved
Sonidegib	The serum concentration of Sonidegib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Spiramycin	The serum concentration of Spiramycin can be decreased when it is combined with Enzalutamide.	Approved
St. John's Wort	The serum concentration of Enzalutamide can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Enzalutamide can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Sulfadiazine	The serum concentration of Sulfadiazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The serum concentration of Sulfamethoxazole can be decreased when it is combined with Enzalutamide.	Approved
Sulfinpyrazone	The serum concentration of Sulfinpyrazone can be decreased when it is combined with Enzalutamide.	Approved
Sulfisoxazole	The metabolism of Enzalutamide can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sunitinib	The serum concentration of Sunitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enzalutamide.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Enzalutamide.	Approved
Tacrolimus	The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Enzalutamide.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tasimelteon	The serum concentration of Tasimelteon can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tasosartan	The serum concentration of Tasosartan can be decreased when it is combined with Enzalutamide.	Approved
Taurochenodeoxycholic acid	The serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Enzalutamide.	Experimental
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Telithromycin	The serum concentration of Telithromycin can be decreased when it is combined with Enzalutamide.	Approved
Temazepam	The serum concentration of Temazepam can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Enzalutamide.	Approved
Teniposide	The serum concentration of Teniposide can be decreased when it is combined with Enzalutamide.	Approved
Terbinafine	The serum concentration of Terbinafine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Terfenadine can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Teriflunomide	The metabolism of Enzalutamide can be decreased when combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Tesmilifene can be decreased when it is combined with Enzalutamide.	Investigational
Testosterone	The serum concentration of Testosterone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Testosterone cypionate	The serum concentration of Testosterone cypionate can be decreased when it is combined with Enzalutamide.	Approved
Testosterone enanthate	The serum concentration of Testosterone enanthate can be decreased when it is combined with Enzalutamide.	Approved
Testosterone propionate	The serum concentration of Testosterone propionate can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The serum concentration of Testosterone undecanoate can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tetracycline	The serum concentration of Tetracycline can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Tezacaftor	The serum concentration of Tezacaftor can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Theophylline	The serum concentration of Theophylline can be decreased when it is combined with Enzalutamide.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Enzalutamide.	Approved, Withdrawn
Thiotepa	The serum concentration of Thiotepa can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tiagabine	The serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Enzalutamide.	Approved
Ticlopidine	The serum concentration of Ticlopidine can be decreased when it is combined with Enzalutamide.	Approved
Tinidazole	The serum concentration of Tinidazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tiotropium	The serum concentration of Tiotropium can be decreased when it is combined with Enzalutamide.	Approved
Tipranavir	The serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be decreased when it is combined with Enzalutamide.	Approved, Withdrawn
Tocilizumab	The serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.	Approved
Tocofersolan	The serum concentration of Tocofersolan can be decreased when it is combined with Enzalutamide.	Approved
Tocopherol	The serum concentration of Tocopherol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tofacitinib	The serum concentration of Tofacitinib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Enzalutamide.	Approved
Topiroxostat	The metabolism of Enzalutamide can be decreased when combined with Topiroxostat.	Approved, Investigational
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Enzalutamide.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trastuzumab	Trastuzumab may increase the cardiotoxic activities of Enzalutamide.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trazodone	The serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Tretinoin	The serum concentration of Tretinoin can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Nutraceutical
Triamcinolone	The serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Trimethadione	The serum concentration of Trimethadione can be decreased when it is combined with Enzalutamide.	Approved
Trimethoprim	The serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.	Approved, Vet Approved
Trimipramine	The serum concentration of Trimipramine can be decreased when it is combined with Enzalutamide.	Approved
Troglitazone	The serum concentration of Troglitazone can be decreased when it is combined with Enzalutamide.	Investigational, Withdrawn
Troleandomycin	The serum concentration of Troleandomycin can be decreased when it is combined with Enzalutamide.	Approved
Udenafil	The serum concentration of Udenafil can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Enzalutamide.	Approved
Ulobetasol	The serum concentration of Ulobetasol can be decreased when it is combined with Enzalutamide.	Approved
Valbenazine	The serum concentration of Valbenazine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Valdecoxib	The serum concentration of Valdecoxib can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Vandetanib	The serum concentration of Vandetanib can be decreased when it is combined with Enzalutamide.	Approved
Vanoxerine	The serum concentration of Vanoxerine can be decreased when it is combined with Enzalutamide.	Investigational
Vardenafil	The serum concentration of Vardenafil can be decreased when it is combined with Enzalutamide.	Approved
Velpatasvir	The serum concentration of Velpatasvir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vemurafenib	The serum concentration of Vemurafenib can be decreased when it is combined with Enzalutamide.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Venlafaxine	The serum concentration of Venlafaxine can be decreased when it is combined with Enzalutamide.	Approved
Verapamil	The serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.	Approved
Vicriviroc	The serum concentration of Vicriviroc can be decreased when it is combined with Enzalutamide.	Investigational
Vilanterol	The serum concentration of Vilanterol can be decreased when it is combined with Enzalutamide.	Approved
Vilazodone	The serum concentration of Vilazodone can be decreased when it is combined with Enzalutamide.	Approved
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Enzalutamide.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vinflunine	The serum concentration of Vinflunine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vinorelbine	The serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be decreased when it is combined with Enzalutamide.	Approved
Voriconazole	The serum concentration of Voriconazole can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Vortioxetine	The serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Voxilaprevir	The serum concentration of Voxilaprevir can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Enzalutamide.	Approved
Yohimbine	The serum concentration of Yohimbine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Vet Approved
Zafirlukast	The serum concentration of Zafirlukast can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Zalcitabine	The serum concentration of Zalcitabine can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Zaleplon	The serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.	Approved, Illicit, Investigational
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide.	Approved
Zileuton	The serum concentration of Zileuton can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Ziprasidone	The serum concentration of Ziprasidone can be decreased when it is combined with Enzalutamide.	Approved
Zolpidem	The serum concentration of Zolpidem can be decreased when it is combined with Enzalutamide.	Approved
Zomepirac	The serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.	Withdrawn
Zonisamide	The serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be decreased when it is combined with Enzalutamide.	Approved
Zotepine	The serum concentration of Zotepine can be decreased when it is combined with Enzalutamide.	Approved, Investigational, Withdrawn
Zuclopenthixol	The serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.	Approved, Investigational

Food Interactions

Not Available

References

General References

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC: NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug;12(8):1629-37. doi: 10.1158/1535-7163.MCT-13-0027. Epub 2013 May 22. [PubMed:23699654]

External Links

KEGG Drug: D10218
PubChem Compound: 15951529
PubChem Substance: 175427141
ChemSpider: 13093347
BindingDB: 50425732
ChEBI: 68534
ChEMBL: CHEMBL1082407
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Enzalutamide

ATC Codes

L02BB04 — Enzalutamide

AHFS Codes

10:00.00 — Antineoplastic Agents

FDA label

Download (393 KB)

MSDS

Download (89.7 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Recruiting	Treatment	Clear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer	1
1	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
1	Active Not Recruiting	Treatment	Bladder Cancers / Renal Pelvis Cancer / Transitional Cell Carcinoma / Ureteral Cancer / Urethral Cancer	1
1	Active Not Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
1	Active Not Recruiting	Treatment	Malignant Neoplasm of Pancreas	1
1	Active Not Recruiting	Treatment	Neoplasms / Solid Cancers	1
1	Active Not Recruiting	Treatment	Prostate Cancer	1
1	Active Not Recruiting	Treatment	Prostatic Neoplasms, Castration-Resistant	1
1	Completed	Not Available	Drug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics	1
1	Completed	Not Available	Healthy Volunteers / Kidney Diseases / Pharmacokinetics of MDV3100	1
1	Completed	Basic Science	Castration Resistant Prostate Cancer (CRPC) / Healthy Volunteers / MDV3100 / Relative Bioavailability	1
1	Completed	Basic Science	Drug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics of Enzalutamide	1
1	Completed	Basic Science	Healthy Volunteers / Pharmacokinetics of MDV3100	1
1	Completed	Basic Science	Normal Hepatic Function / Severe Hepatic Impairment	1
1	Completed	Basic Science	Pharmacokinetics of Caffeine / Pharmacokinetics of Dextromethorphan / Prostate Cancer	1
1	Completed	Basic Science	Pharmacokinetics of Enzalutamide / Prostate Cancer	1
1	Completed	Treatment	Cancer, Breast	1
1	Completed	Treatment	Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma	1
1	Completed	Treatment	Castration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV3100	1
1	Completed	Treatment	Hormone Refractory Prostate Cancer / Prostate Cancer	1
1	Completed	Treatment	Prostate Cancer	1
1	Not Yet Recruiting	Other	Prostate Cancer	1
1	Not Yet Recruiting	Treatment	Malignant Neoplasm of Breast	1
1	Recruiting	Treatment	Advanced Solid Tumors / Cancer, Breast / Prostate Cancer	1
1	Recruiting	Treatment	Cancers	1
1	Recruiting	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Cancer	1
1	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms	1
1	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1	Recruiting	Treatment	Prostate Cancer	1
1	Recruiting	Treatment	Tumors, Solid	1
1	Terminated	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
1	Withdrawn	Treatment	Cancers	1
1, 2	Active Not Recruiting	Treatment	Metastatic Castrate-Resistant Prostate Cancer	1
1, 2	Completed	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Cancer / Prostate Neoplasms	1
1, 2	Recruiting	Treatment	Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Estrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma	1
1, 2	Recruiting	Treatment	Hepatocellular,Carcinoma	1
1, 2	Recruiting	Treatment	Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
1, 2	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	2
1, 2	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
2	Active Not Recruiting	Basic Science	Metastatic Hormone Refractory Prostate Cancer	1
2	Active Not Recruiting	Other	Metastatic Castration Resistant Prostate Cancer	1
2	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate	1
2	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
2	Active Not Recruiting	Treatment	Adenocarcinoma, Prostate / High Risk Prostate Cancer / Prostate Cancer	1
2	Active Not Recruiting	Treatment	Advanced Breast Cancer / HER2 Amplified / Human Epidermal Growth Factor Receptor 2 (HER2)	1
2	Active Not Recruiting	Treatment	Advanced Hepatocellular Carcinoma	1
2	Active Not Recruiting	Treatment	Advanced, Androgen Receptor Positive Triple Negative Breast Cancer	1
2	Active Not Recruiting	Treatment	Cancer, Breast	1
2	Active Not Recruiting	Treatment	Castration Resistant Prostate Cancer (CRPC) / Prostate Carcinoma Metastatic to the Bone	1
2	Active Not Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Active Not Recruiting	Treatment	Hormone-Refractory Prostate Cancer	1
2	Active Not Recruiting	Treatment	Intermediate Risk Prostate Cancer	1
2	Active Not Recruiting	Treatment	Metastatic Castration-Resistant Prostatic Cancer	1
2	Active Not Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Active Not Recruiting	Treatment	Non-metastatic, Hormone naïve Prostate Cancer	1
2	Active Not Recruiting	Treatment	Prostate Cancer	10
2	Active Not Recruiting	Treatment	Prostate Carcinoma Metastatic to the Bone	1
2	Active Not Recruiting	Treatment	Prostatic Neoplasms	1
2	Completed	Treatment	Androgen Receptor Abnormal / DNA / Prostate Cancer	1
2	Completed	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
2	Completed	Treatment	Castration-Resistant Prostate Cancer (CRPC) / Prostate Cancer	1
2	Completed	Treatment	Metastatic Castration Resistant Prostate Cancer	1
2	Completed	Treatment	Metastatic Progressive Castration-resistant Prostate Cancer	1
2	Completed	Treatment	Prostate Cancer	4
2	Completed	Treatment	Prostatic Neoplasms	1
2	Not Yet Recruiting	Treatment	Castration-Resistant Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer	1
2	Recruiting	Other	Metastatic Castrate-resistant Prostate (CRPC) Cancer	1
2	Recruiting	Supportive Care	Adenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer	1
2	Recruiting	Treatment	Adenocarcinoma of the Prostate	2
2	Recruiting	Treatment	Adenocarcinoma, Prostate / Prostate Cancer	1
2	Recruiting	Treatment	Advanced Epithelial Ovarian / Fallopian Tubes / Primary Peritoneal Carcinoma / Recurrent Epithelial Ovarian	1
2	Recruiting	Treatment	Bone Metastases / Castration-Resistant Prostate Cancer (CRPC)	1
2	Recruiting	Treatment	Bone Metastases / Prostate Cancer	1
2	Recruiting	Treatment	Cancer of the Ovary	1
2	Recruiting	Treatment	Cancer of the Prostate / Prostate Cancer	1
2	Recruiting	Treatment	Cancer, Breast	3
2	Recruiting	Treatment	Cancer, Breast / Early Stage / Triple Negative Breast Cancer (TNBC)	1
2	Recruiting	Treatment	Castration Resistant Metastatic Prostate Cancer	1
2	Recruiting	Treatment	Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma AJCC v7 / Stage IV Prostate Cancer	1
2	Recruiting	Treatment	Endometrial Cancers	1
2	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
2	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	3
2	Recruiting	Treatment	Pelvic Nodal / Prostatic Neoplasms	1
2	Recruiting	Treatment	Primary Breast Cancer AR+ve TNBN / Primary Breast Cancer ER+ve	1
2	Recruiting	Treatment	Prostate Cancer	10
2	Recruiting	Treatment	Prostatic Neoplasms	1
2	Recruiting	Treatment	Salivary Cancer	1
2	Terminated	Prevention	Bladder Cancers	1
2	Withdrawn	Treatment	Localized Prostate Cancer / Prostate Cancer	1
2	Withdrawn	Treatment	Metastatic Castration Resistant Prostate Cancer	1
2, 3	Recruiting	Treatment	Castration-resistant Prostate Cancer Patients With Oligometastases	1
2, 3	Recruiting	Treatment	Metastasis / Metastatic Hormone Refractory Prostate Cancer	1
2, 3	Recruiting	Treatment	Prostate Cancer	1
3	Active Not Recruiting	Treatment	Adenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer	1
3	Active Not Recruiting	Treatment	Cancer of the Prostate / Nonmetastatic Castration-Resistant Prostate Cancer / Prostate Cancer	1
3	Active Not Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
3	Active Not Recruiting	Treatment	Metastatic Hormone Sensitive Prostate Cancer	1
3	Active Not Recruiting	Treatment	Progressive Metastatic Prostate Cancer	1
3	Active Not Recruiting	Treatment	Prostate Cancer	1
3	Active Not Recruiting	Treatment	Prostatic Neoplasms	1
3	Completed	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
3	Recruiting	Treatment	Cancer of the Prostate / Hormone Sensitive Prostate Cancer / Prostate Cancer	1
3	Recruiting	Treatment	Cancer, Breast	1
3	Recruiting	Treatment	Metastatic Castration Resistant Prostate Cancer	1
3	Recruiting	Treatment	Prostate Cancer	1
3	Recruiting	Treatment	Prostatic Neoplasms	1
3	Recruiting	Treatment	Prostatic Neoplasms, Castration-Resistant	1
3	Terminated	Treatment	Prostate Cancer	1
4	Active Not Recruiting	Treatment	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
4	Active Not Recruiting	Treatment	Prostate Cancer	2
4	Completed	Treatment	Metastatic Castration Resistant Prostate Cancer	1
4	Recruiting	Supportive Care	Castration-Resistant Prostatic Cancer / Hormone-Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
4	Recruiting	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
4	Terminated	Treatment	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Active Not Recruiting	Not Available	Adenocarcinoma, Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer	1
Not Available	Active Not Recruiting	Not Available	Castration-Resistant Prostate Cancer (CRPC)	1
Not Available	Active Not Recruiting	Not Available	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Active Not Recruiting	Not Available	Prostatic Neoplasms, Castration-Resistant	1
Not Available	Active Not Recruiting	Treatment	Prostate Cancer	1
Not Available	Approved for Marketing	Not Available	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Completed	Not Available	Metastatic Castration Resistant Prostate Cancer	1
Not Available	Recruiting	Not Available	Prostate Cancer	1
Not Available	Recruiting	Treatment	Adenocarcinoma of the Prostate / Castration Levels of Testosterone / Castration-Resistant Prostate Carcinoma / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma in the Soft Tissue / Metastatic Prostatic Adenocarcinoma / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Cancer / Recurrent Prostate Carcinoma / Stage III Prostate Adenocarcinoma / Stage IV Prostate Adenocarcinoma / Stage IV Prostate Cancer	1
Not Available	Recruiting	Treatment	Adenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Stage IV Prostate Cancer	1
Not Available	Recruiting	Treatment	Ann Arbor Stage I Mantle Cell Lymphoma / Ann Arbor Stage II Mantle Cell Lymphoma / Ann Arbor Stage III Mantle Cell Lymphoma / Ann Arbor Stage IV Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma	1
Not Available	Recruiting	Treatment	Castration-Resistant Prostate Cancer (CRPC)	1
Not Available	Terminated	Treatment	Prostate Cancer	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral	40 mg
Capsule	Oral	40 mg/1

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8183274	No	2006-05-15	2026-05-15
US9126941	No	2006-05-15	2026-05-15
US7709517	No	2007-08-13	2027-08-13

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Insoluble	FDA label

Predicted Properties

Property	Value	Source
Water Solubility	0.00136 mg/mL	ALOGPS
logP	3.75	ALOGPS
logP	4.16	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Acidic)	13.05	ChemAxon
pKa (Strongest Basic)	-1.7	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	76.44 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	113.48 m³·mol^-1	ChemAxon
Polarizability	42.71 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9356
Blood Brain Barrier	+	0.8514
Caco-2 permeable	+	0.5219
P-glycoprotein substrate	Non-substrate	0.7609
P-glycoprotein inhibitor I	Inhibitor	0.6464
P-glycoprotein inhibitor II	Inhibitor	0.5693
Renal organic cation transporter	Non-inhibitor	0.899
CYP450 2C9 substrate	Non-substrate	0.7447
CYP450 2D6 substrate	Non-substrate	0.8061
CYP450 3A4 substrate	Substrate	0.5589
CYP450 1A2 substrate	Non-inhibitor	0.5613
CYP450 2C9 inhibitor	Inhibitor	0.7126
CYP450 2D6 inhibitor	Non-inhibitor	0.9148
CYP450 2C19 inhibitor	Inhibitor	0.6882
CYP450 3A4 inhibitor	Inhibitor	0.6184
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.6711
Ames test	Non AMES toxic	0.683
Carcinogenicity	Non-carcinogens	0.7232
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4319 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9911
hERG inhibition (predictor II)	Inhibitor	0.7079

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-014i-0321900000-b1c610c4a717fdea030e

Taxonomy

Description: This compound belongs to the class of organic compounds known as phenylimidazolidines. These are polycyclic compounds containing an imidazoline substituted by a phenyl group.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Azolidines
Sub Class: Imidazolidines
Direct Parent: Phenylimidazolidines
Alternative Parents: Trifluoromethylbenzenes / 2-halobenzoic acids and derivatives / Alpha amino acids and derivatives / N-phenylthioureas / Benzamides / Benzoyl derivatives / Benzonitriles / Fluorobenzenes / Aryl fluorides / Imidazolidinones
show 11 more
Substituents: Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / N-phenylthiourea / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Benzonitrile / Benzoyl
show 29 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: benzamides, nitrile, imidazolidinone, monofluorobenzenes, (trifluoromethyl)benzenes, thiocarbonyl compound (CHEBI:68534)

Targets

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	>100000	N/A	N/A	23301637

Details1. Androgen receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Inhibitor

General Function: Zinc ion binding
Specific Function: Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name: AR
Uniprot ID: P10275
Uniprot Name: Androgen receptor
Molecular Weight: 98987.9 Da

Enzymes

Details1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C8
Uniprot ID: P10632
Uniprot Name: Cytochrome P450 2C8
Molecular Weight: 55824.275 Da

Details2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate
Inducer

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

Details3. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2C9
Uniprot ID: P11712
Uniprot Name: Cytochrome P450 2C9
Molecular Weight: 55627.365 Da

Details4. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name: CYP2C19
Uniprot ID: P33261
Uniprot Name: Cytochrome P450 2C19
Molecular Weight: 55930.545 Da

Details5. Cytochrome P450 2B6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP2B6
Uniprot ID: P20813
Uniprot Name: Cytochrome P450 2B6
Molecular Weight: 56277.81 Da

Details6. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Steroid hydroxylase activity
Specific Function: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name: CYP2D6
Uniprot ID: P10635
Uniprot Name: Cytochrome P450 2D6
Molecular Weight: 55768.94 Da

Details7. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Oxygen binding
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name: CYP3A5
Uniprot ID: P20815
Uniprot Name: Cytochrome P450 3A5
Molecular Weight: 57108.065 Da

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

Transporters

Details1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Xenobiotic-transporting atpase activity
Specific Function: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name: ABCB1
Uniprot ID: P08183
Uniprot Name: Multidrug resistance protein 1
Molecular Weight: 141477.255 Da

Drug created on June 04, 2013 23:12 / Updated on April 23, 2018 23:12

Enzalutamide

Identification

Structure for DB08899 (Enzalutamide)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

Enzymes

Carriers

Transporters